Fig. 4

Alterations in CD56^bright NK cell receptors between 0 and 6 months in control, moderate and severe CFS/ME patients. a Percentage of CD56^brightCD16^dim NK cells expressing KIR3DL1/DL2. b Percentage of total CD56^brightCD16⁺ NK cells expressing KIR2DL1. c Percentage of CD56^brightCD16⁺ NK cells expressing KIR2DL2/DL3. d Percentage of CD56^brightCD16⁺ NK cells expressing KIR2DS4. Data is shown as mean ± SEM where statistical significance was accepted as p < 0.05. NK Natural Killer, CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, SEM standard error of the mean